Praxis Precision Medicines, Inc. (PRAX)
PRAX Stock Price Chart
Explore Praxis Precision Medicines, Inc. interactive price chart. Choose custom timeframes to analyze PRAX price movements and trends.
PRAX Company Profile
Discover essential business fundamentals and corporate details for Praxis Precision Medicines, Inc. (PRAX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Oct 2020
Employees
116.00
Website
https://www.praxismedicines.comCEO
Marcio Silva De'Souza
Description
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
PRAX Financial Timeline
Browse a chronological timeline of Praxis Precision Medicines, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Aug 2026
EPS estimate is -$3.67, while revenue estimate is $1.25m.
Earnings released on 7 May 2026
EPS came in at -$3.20 surpassing the estimated -$3.58 by +10.61%.
Earnings released on 19 Feb 2026
EPS came in at -$3.50 falling short of the estimated -$3.13 by -11.97%.
Earnings released on 5 Nov 2025
EPS came in at -$3.36 surpassing the estimated -$3.45 by +2.61%.
Earnings released on 4 Aug 2025
EPS came in at -$3.31 surpassing the estimated -$3.40 by +2.65%.
Earnings released on 2 May 2025
EPS came in at -$3.29 falling short of the estimated -$3.20 by -2.81%.
Earnings released on 28 Feb 2025
EPS came in at -$2.94 falling short of the estimated -$2.76 by -6.52%, while revenue for the quarter reached $7.46m , beating expectations by +2.41k%.
Earnings released on 6 Nov 2024
EPS came in at -$2.75 falling short of the estimated -$2.01 by -36.82%, while revenue for the quarter reached $302.00k , missing expectations by -17.26%.
Earnings released on 13 Aug 2024
EPS came in at -$1.74 surpassing the estimated -$2.38 by +26.89%, while revenue for the quarter reached $357.00k , missing expectations by -56.99%.
Earnings released on 13 May 2024
EPS came in at -$2.84 falling short of the estimated -$2.01 by -41.29%, while revenue for the quarter reached $431.00k , missing expectations by -73.40%.
Earnings released on 5 Mar 2024
EPS came in at -$2.97 surpassing the estimated -$3.15 by +5.71%, while revenue for the quarter reached $515.00k , beating expectations by +930.00%.
Stock split effective on 29 Nov 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 Nov 2023
EPS came in at -$2.70 surpassing the estimated -$5.25 by +48.57%, while revenue for the quarter reached $468.00k .
Earnings released on 9 Aug 2023
EPS came in at -$7.35 surpassing the estimated -$9.90 by +25.76%, while revenue for the quarter reached $781.00k .
Earnings released on 11 May 2023
EPS came in at -$10.64 surpassing the estimated -$11.24 by +5.34%, while revenue for the quarter reached $683.00k .
Earnings released on 7 Feb 2023
EPS came in at -$13.04 falling short of the estimated -$10.94 by -19.20%.
Earnings released on 9 Nov 2022
EPS came in at -$14.39 falling short of the estimated -$13.79 by -4.35%.
Earnings released on 8 Aug 2022
EPS came in at -$19.79 falling short of the estimated -$19.49 by -1.54%.
Earnings released on 9 May 2022
EPS came in at -$22.64 falling short of the estimated -$19.34 by -17.06%.
Earnings released on 28 Feb 2022
EPS came in at -$19.49 falling short of the estimated -$16.19 by -20.38%.
Earnings released on 3 Nov 2021
EPS came in at -$14.99 falling short of the estimated -$13.94 by -7.53%.
Earnings released on 16 Aug 2021
EPS came in at -$13.19 falling short of the estimated -$10.19 by -29.44%.
PRAX Stock Performance
Access detailed PRAX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
